Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

September 9th 2021

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Final Thoughts on New Developments and Emerging Agents

September 9th 2021

Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.

Treatment Approaches for TP53-Mutated AML

September 9th 2021

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Future Directions in MDS

September 9th 2021

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.

MDS Treatment Selection: Impact of QoL

September 9th 2021

Drs Madanat and Sekeres comment on the importance of quality of life and patient perspective in the selection of MDS treatment.

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

September 8th 2021

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

Dr. Cortes on Emerging Therapies in CML

September 8th 2021

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

September 8th 2021

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

Challenges in Myelofibrosis Treatment

September 7th 2021

Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.

Treatment Strategies for Primary Myelofibrosis

September 7th 2021

Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.

European Commission Expands Ravulizumab-cwvz Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication

September 3rd 2021

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Unmet Needs in MDS

September 2nd 2021

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, highlight unmet needs in the treatment of patients with high-risk MDS.

MDS: Clinical Primary Endpoints

September 2nd 2021

Experts in the treatment of MDS explore clinically meaningful treatment endpoints, including complete responses, bone marrow complete responses, and overall survival outcomes in MDS.

Pevonedistat/Azacitidine Misses EFS End Point in Frontline Higher-Risk MDS/CMML, Low-Blast AML

September 2nd 2021

The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.

Evolving Treatment Approaches Pre- and Post-Transplant

September 2nd 2021

Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.